Introduction
Recepteur d" origine nantais (RON), a tyrosine kinase receptor, for macrophage stimulating protein (MSP) was reported to be over-expressed in various cancers of epithelial origin (1, 2) . Activation of the RON receptor in breast cancer cells is linked to tamoxifen resistance (3) . Further, gene expression analyses suggested that increase in RON expression is associated with metastatic disease. Transgenic mice that over-express a wild type or constitutively active RON receptor in the mammary epithelium induced mammary transformation and associated with a high degree of metastasis (4) . Aberrant RON expression in human breast cancer is associated with an aggressive cancer phenotype with decreased disease free survival time in patients and an increase in breast cancer metastasis (5) . These studies demonstrated that RON over-expression can be a causative factor for metastatic breast cancer. Nrf2 (NF-E2-related factor 2) belongs to the cap "n" collar subfamily of basic-leucine zipper family of transcription factors (6) . Its role in chemoprevention as the inducer of several hundred cytoprotective genes which contain one or more antioxidant response elements (ARE: 5"-TGACnnnGC-3") is well documented (7) . Nrf2 null mice are susceptible to carcinogen induced cancer development (8) (9) (10) (11) (12) . Nrf2 activity is regulated by keap1 (kelch-like ECH-associated protein 1). Keap1 serves as an adapter protein for interaction of cul3-based E3-ubiquitin ligase complex with Nrf2 leading to continuous ubiquitination of Nrf2 and its proteasomal degradation (13) . Activators of Nrf2 like sulforaphane (SFN), an isothiocyanate, have been shown to modify the keap1 protein leading to the dissociation of Nrf2-keap1 complex resulting in the escape of Nrf2 from proteasomal degradation (14) . Nrf2 was reported to be depleted in breast cancer cell lines (15) . The data presented in this manuscript indicate depletion of Nrf2 is prevalent in breast tumors and is associated with overexpression of RON. We also report that Nrf2 binds a closely related cis-element (5"-TGA(C/G)TCA-3") to ARE but displays a novel function as an inhibitor of oncogene RON 
Real-Time Reverse Transcriptase-Polymerase
Chain Reaction: 100 ng of total RNA was subjected to real-time RT-PCR reaction with SYBR Green real-time PCR mix (Bio-Rad Laboratories). Primers for RON: sense primers, 5"-AGC CCA CGC TCA GTG TCT AT-3"; antisense primers, 5"-GGG CAC TAG GAT CAT CTG TCA-3". Primers for Nrf2: sense primers, 5"-CGG TAT GCA ACA GGA CAT TG-3"; antisense primers, 5"-ACT GGT TGG GGT CTT CTG TG-3". Primers for actin: sense primers, 5"-ACA CTG TGC CCA TCT ACG AGG-3"; antisense primers, 5"-AGG GGC CGG ACT CGT CAT ACT-3". The β-actin mRNA was amplified simultaneously for an endogenous control. Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR): Primers for RON generate a 246-bp fragment as follows: sense primers, 5"-AGC CCA CGC TCA GTG TCT AT-3"; antisense primers, 5"-GGG CAC TAG GAT CAT CTG TCA-3". Primers for Nrf2 generate a 280-bp fragment as follows: sense primers, 5"-CGG TAT GCA ACA GGA CAT TG-3"; antisense primers, 5"-ACT GGT TGG GGT CTT CTG TG-3". Primers for actin generate a 621 bp fragment as follows: sense primers, 5"-ACA CTG TGC CCA TCT ACG AGG-3"; antisense primers, 5"-AGG GGC CGG ACT CGT CAT ACT-3". Invasion assay: The invasive behavior of cancer cells was analyzed as described previously (16) . Quantification data represents the mean ± S.D. of three separate invasion assays.
Chromatin Immunoprecipitation assay (ChIP):
The ChIP assay was performed as described previously (16) . RON promoter primers covering the Nrf2 sites were used to carry out PCR on DNA isolated from chromatin immunoprecipitation using control IgG or Nrf2 antibodies. Primers used to generate a 293 bp fragment covering the Nrf2 binding sites on the RON promoter. Forward: 5"-CTC CAA GGG CCG GAA GAG TCG GAT GG-3"; Reverse: 5"-TTA AGC AGC GGT CCC GAC AGC CCC AA-3". Construction of -400 bp wild type/Nrf2 sites mutant RON promoter-luciferase reporter constructs: The 400 bp RON promoter-luciferase reporter was described previously (16) . The Nrf2 sites specific mutant constructs of the RON promoter was generated using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) based on the 400 bp RON promoterluciferase reporter construct as a template. The mutations were confirmed by DNA sequencing. The oligonucleotide sequences used to generate Nrf2 1m mutant construct is: wild type primer 5"-GCCCTCGGGTCTGAGCACCTGACGCCTGC GGACG-3"; mutant primer 5"-GCCCTCGGGTCGAGGCACCGAGCGCCTGC GGACG-3". The oligonucleotide sequences used to generate Nrf2 2m mutant construct is: wild type primer 5"-CCCGCCCCAGGTTCCTGTGAAACCCAAAT CCCTTCC-3"; mutant primer 5"-CCCGCCCCAGGTTCCTGGAGAACCCAAAT CCCTTCC-3". Luciferase assay: Luciferase assays were performed as described previously (16 1C ). As previously reported Nrf2 message is detected since Nrf2 expression is regulated through a post-transcriptional mechanism (15).
SFN-mediated Nrf2 stabilization blocks RON expression and invasion of carcinoma cells:
Chemoprevention agent SFN has been documented to modify the keap1 protein leading to the dissociation of Nrf2-keap1 complex and thus stabilizing the Nrf2 protein (14 figs.1-3 ). Nrf2 role as a "repressor" of RON gene expression was further validated by our studies where ectopic expression of Nrf2 negative regulator, keap1 led to a decrease in the Nrf2 levels with a concomitant increase in the RON expression in the normal human mammary epithelial cells (supplementary fig.4 ). As illustrated in fig.4D , we have shown that increasing Nrf2 expression through Nrf2 activator SFN or ectopic Nrf2 expression or keap1 knockdown "inhibits" RON expression and consequently blocks RON ligand MSP induced invasion of carcinoma cells. Consequently, our studies identified a novel functional role for Nrf2 as a "repressor" of an oncogene and RON kinase as one of the potential molecular targets of SFN which mediates the anti-tumor effects of SFN. Keap1 Clones Keap1 Clones
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